NeuroBo Pharmaceuticals: Promising Results for Vanoglipel in Treating Metabolic Dysfunction and Liver Disease

Novel Therapy Shows Promise in Combatting Metabolic Dysfunction-Associated Steatohepatitis

MetaVia Inc. announces significant findings from its Phase 2a clinical trial of vanoglipel (DA-1241), a selective G protein-coupled receptor 119 (GPR119) agonist, designed to address metabolic dysfunction-associated steatohepatitis (MASH). The trial includes 109 participants diagnosed with presumed MASH, who were randomly assigned to receive either a placebo, vanoglipel doses of 50 mg or 100 mg, or a combination of 100 mg vanoglipel with a dipeptidyl peptidase-4 inhibitor (DPP4i) once daily over a 16-week period. The results, which are set to be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, reveal notable improvements in key health indicators, such as glucose control, liver health, and lipid profiles in the participants.

The trial's findings indicate that vanoglipel significantly lowers HbA1c levels in individuals with type 2 diabetes and prediabetes while also ameliorating liver inflammation, fibrosis, and steatosis. This dual-action mechanism of vanoglipel enhances glucagon-like peptide-1 (GLP-1) secretion and is further potentiated by the DPP4i, maximizing therapeutic benefits across metabolic and hepatic pathways. These results underscore the potential of vanoglipel as a stand-alone oral therapy, offering a multifaceted approach to managing the intricate relationship between metabolic dysfunction and liver disease.

Hyung Heon Kim, President and CEO of MetaVia, expresses optimism about vanoglipel's future, both as a monotherapy and in combination therapies targeting MASH and related metabolic disorders. The trial’s promising outcomes reflect an urgent need for effective treatments in a field that has seen limited therapeutic options. The data generated from this study could pave the way for new interventions in the management of MASH, highlighting the importance of innovative approaches in addressing complex metabolic health challenges.

In addition to the clinical trial results, the development of vanoglipel comes at a critical time as the prevalence of metabolic disorders continues to rise globally. The innovative mechanism of vanoglipel not only addresses liver health but also encompasses broader metabolic concerns, positioning MetaVia as a key player in the biotechnology landscape focused on chronic liver diseases.

The findings of this trial may also provide momentum for further research into GPR119 agonists, which could lead to more comprehensive treatment strategies. As healthcare providers seek effective solutions for patients suffering from metabolic dysfunction and liver disease, vanoglipel's differentiated approach may offer new hope in managing these intertwined conditions effectively.